Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02598557 |
Recruitment Status :
Active, not recruiting
First Posted : November 6, 2015
Last Update Posted : December 20, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stage 0 Breast Cancer AJCC v6 and v7 Stage I Breast Cancer AJCC v7 Stage IA Breast Cancer AJCC v7 Stage IB Breast Cancer AJCC v7 Stage II Breast Cancer AJCC v6 and v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 | Drug: Exemestane Other: Laboratory Biomarker Analysis Other: Pharmacological Study Other: Placebo Administration Other: Quality-of-Life Assessment Other: Questionnaire Administration Procedure: Therapeutic Conventional Surgery | Phase 2 |
PRIMARY OBJECTIVE:
I. Non-inferiority of percent change in time of serum unconjugated estradiol levels, adjusted for baseline levels, following four up to six weeks of exemestane 25 mg given three times per week or one time per week compared with exemestane 25 mg daily dosing.
SECONDARY OBJECTIVES:
I. To assess safety and toxicity. II. To support the preventive activity of exemestane we will investigate the change in Ki-67 and progesterone receptor (PgR) levels in tumor cells and the adjacent intraepithelial neoplasia or benign histologic structures.
III. To assess possible association of estradiol level with tissue and circulating biomarkers.
IV. To investigate possible pharmacogenetic markers. V. To assess drug levels on tissue samples. VI. To investigate tissue proteomics profiling.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive exemestane orally (PO) once daily (QD) on days 1-7.
ARM II: Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7.
ARM III: Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7.
In all arms, cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
After completion of study treatment, patients are followed up at 20-30 days.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 180 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Prevention |
Official Title: | Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial |
Actual Study Start Date : | December 6, 2016 |
Actual Primary Completion Date : | October 3, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm I (exemestane)
Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
|
Drug: Exemestane
Given PO
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies Procedure: Therapeutic Conventional Surgery Undergo surgery |
Experimental: Arm II (exemestane, placebo)
Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
|
Drug: Exemestane
Given PO
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Other: Placebo Administration Given PO Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies Procedure: Therapeutic Conventional Surgery Undergo surgery |
Experimental: Arm III (exemestane, placebo)
Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
|
Drug: Exemestane
Given PO
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Other: Placebo Administration Given PO Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies Procedure: Therapeutic Conventional Surgery Undergo surgery |
- Percentage change of serum unconjugated estradiol concentration [ Time Frame: Baseline to up to day 43 ]Full distribution and median values of estradiol at baseline (before treatment), at post (after treatment) will be presented, and changes and percentage changes (with interquartile ranges) of estradiol level, from baseline to post, by arms. Differences by arms of percent change, change and final values will be tested considering t-test and analysis of covariance (ANCOVA) models. Estradiol at baseline will be included as explanatory variable together with other possible confounders such as BMI, age and time since last dose. Normal distribution of residuals from full model will be checked and, if needed, a transformation will be considered. Percentages of patients with final values of estradiol below the detectable level will be compared by arms with Chi-square tests and logistic models.
- Incidence of toxicity graded according to the Common Terminology Criteria for Adverse Events version 4.0 and Menopause-Specific Quality of Life Questionnaire [ Time Frame: Up to day 43 ]
- Change in Ki67 expression [ Time Frame: Baseline to up to day 43 ]Full distributions and median values of circulating biomarkers, Ki67, in tissue at baseline, after treatment and also of changes and percentage changes (with interquartile ranges) of all continuous variable, will be presented by arms. ANCOVA models will evaluate the associations of post values (after treatment) and changes from baseline by study arms adjusting for baseline values, explanatory variables and possible confounders (such as age and BMI). Normal distribution of residuals from full models will be checked and, if needed, a transformation will be considered.
- Change in serum drug measurements of exemestane and 17-dihydroxyexemestane at the end of treatment [ Time Frame: Baseline to up to day 43 ]Full distributions and median values of circulating biomarkers, exemestane and 17dihydroxyexemestane in tissue at baseline, after treatment and also of changes and percentage changes (with interquartile ranges) of all continuous variable, will be presented by arms. ANCOVA models will evaluate the associations of post values (after treatment) and changes from baseline by study arms adjusting for baseline values, explanatory variables and possible confounders (such as age and BMI). Normal distribution of residuals from full models will be checked and, if needed, a transformation will be considered.
- Serum concentrations of unconjugated and total estrone and estrone sulfate measured by liquid chromatography coupled with tandem mass spectrometry [ Time Frame: Up to day 43 ]
- Serum concentrations of androstenedione and testosterone measured by liquid chromatography coupled with tandem mass spectrometry [ Time Frame: Up to day 43 ]
- Serum testosterone determined by a chemiluminescent immunoassay [ Time Frame: Up to day 43 ]
- Sex hormone binding globulin serum levels measured by a chemiluminescent microparticle immunoassay [ Time Frame: Up to day 43 ]
- Change in concentrations of insulin, glucose (homeostatic model assessment index), and lipid profile (total cholesterol, high-density lipoprotein cholesterol and triglycerides [ Time Frame: Baseline up to day 43 ]
- Change in leptin and adiponectin serum concentrations measured by enzyme linked immunoassays [ Time Frame: Baseline to up to day 43 ]The change in leptin and adiponectin serum concentrations will be analyzed and compared among the different treatment arms.
- Measurement exemestane and 17-dihydroxyexemestane [ Time Frame: Up to day 43 ]Will be performed on frozen tissue samples (normal breast and breast cancer tissue).
- Breast estradiol and estrone concentration in tumor and normal breast tissue [ Time Frame: At time of surgery ]
- Changes in estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki67 expression levels [ Time Frame: Baseline to up to day 43 ]
- Ki67 in adjacent intraepithelial neoplasia and or grossly benign tissue [ Time Frame: Up to day 43 ]
- Proteomic analysis [ Time Frame: Up to day 43 ]
- UGT2B17 gene analysis assessed by the Taqman copy number variation assay [ Time Frame: Up to day 43 ]
- Changes in the occurrence of crown like structures in mammary fat tissue by immunohistochemistry [ Time Frame: Baseline to up to day 43 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 75 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Postmenopausal women (postmenopausal: age >= 60 years, or amenorrhea >= 12 months, or bilateral oophorectomy, or - in women with hysterectomy only - follicle stimulating hormone [FSH] in the menopausal levels as per local institutional guidelines if < 60 years old) with histologically-confirmed estrogen receptor (ER)-positive (>= 10%) primary breast cancer stage cT0-2, cN0-1, Mx; women with larger tumors who refuse chemotherapy (chemo) and/or endocrine neoadjuvant therapy can be eligible
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
- Leukocytes >= 3,000/microliter
- Absolute neutrophil count >= 1,500/microliter
- Platelets >= 100,000/microliter
- Total bilirubin =< 2 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional ULN
- Serum creatinine =< 1.5 times institutional ULN
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Body mass index (BMI) < 18.5 Kg/m^2
- Previous treatment for breast cancer including chemotherapy, endocrine therapy and radiotherapy; women with prior ductal breast carcinoma in situ (DCIS) who were treated with surgery only and whose treatment ended >= 2 years prior to enrollment are eligible for the trial
- Women who are planned to receive neoadjuvant therapy
- Participants may not be receiving investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Other co-existing invasive malignancies (with the exclusion of basal cell carcinoma or skin squamous cell carcinoma) diagnosed during the last 2 years before randomization
- History of severe osteoporosis (T score =< -4 either spine or hip), or presence of vertebral fracture
- Use of systemic hormone replacement therapy (HRT) in the last 30 days prior to the randomization; the use of non-systemic estrogen (such as vaginal estrogen use) is allowed
- Use of any chemopreventive agents (selective estrogen receptor modulators [SERM]) in the last 3 months
- Concomitant use of CYP3A4 inducer medication (rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John's wort)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02598557
United States, Florida | |
Moffitt Cancer Center | |
Tampa, Florida, United States, 33612 | |
United States, New York | |
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | |
New York, New York, United States, 10032 | |
United States, Texas | |
M D Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
Italy | |
Galliera Hospital | |
Genoa, Italy, 16128 | |
European Institute of Oncology | |
Milano, Italy, 20141 |
Principal Investigator: | Bernardo Bonanni | M.D. Anderson Cancer Center |
Documents provided by National Cancer Institute (NCI):
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT02598557 |
Other Study ID Numbers: |
NCI-2015-01821 NCI-2015-01821 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) HHSN26120120034I N01-CN-2012-00034 2016-0276 ( Other Identifier: M D Anderson Cancer Center ) MDA2014-04-01 ( Other Identifier: DCP ) N01CN00034 ( U.S. NIH Grant/Contract ) P30CA016672 ( U.S. NIH Grant/Contract ) |
First Posted: | November 6, 2015 Key Record Dates |
Last Update Posted: | December 20, 2021 |
Last Verified: | June 2021 |
Breast Neoplasms Breast Carcinoma In Situ Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Carcinoma in Situ Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Exemestane Antineoplastic Agents Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |